Description:

Study ID: 103974 (primary study) Clinical Study ID: 103974 Study Title: Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00258700 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENC-TT; Menitorix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis

Keywords:
Versions (1) ▾
  1. 1/10/19
Copyright Holder:
GSK group of companies
Uploaded on:

January 10, 2019

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Primary & Booster Immunogenicity of Hib-MenC vs a Licensed Men-C Vaccine - 103974

Diary Cards for Dose 3 (Primary)

Administrative data
Dose 3 - Local Symptoms - Vaccine 1
Redness (Local Symptoms)
mm
Swelling (Local Symptoms)
mm
Pain (Local Symptoms)
Dose 3 - Local Symptoms - Vaccine 2
Redness (Local Symptoms)
mm
Swelling (Local Symptoms)
mm
Pain (Local Symptoms)
Dose 3 - Other Local Symptoms
Dose 3 - General Symptoms
Temperature (General Symptoms)
°C
Irritability / Fussiness (General Symptoms)
Drowsiness (General Symptoms)
Loss of Appetite (General Symptoms)
Dose 3 - Other General Symptoms
Dose 3 - Medication
Reminder